Laidback Al
Well-known member
Travel Med Infect Dis. 2010 Jan;8(1):1-12. Epub 2009 Dec 1.
Avian influenza ? A review for doctors in travel medicine
<form class="form" method="get" name="authors1" action="/search/quick"><input name="search_medline" value="yes" type="hidden"><input name="search_area" value="platform+medline" type="hidden"><input name="restrictname_author" value="author" type="hidden"><input name="restricttype_author" value="author" type="hidden"><input name="restrictterm_author" value="" type="hidden"><input name="restrictdesc_author" value="" type="hidden">W.R.J. Taylorab, E. Burhanc, H. Wertheima, P.Z. Soepandic, P. Horbya, A. Foxa, R. Benamored, L. de Simonee, T.T. Hienf, F. Chappuisb</form>Received 29 October 2009; received in revised form 10 November 2009; accepted 10 November 2009. published online 02 December 2009.
Summary
First identified in humans in Hong Kong, influenza A/H5N1, known commonly as avian influenza, has caused human disease in 15 countries around the world. Although the current number of confirmed patients is tiny compared to seasonal and the recently emerged H1N1 ?swine? influenza, H5N1 remains a candidate for the next highly pathogenic influenza pandemic. Currently, H5N1 has very limited ability to spread from person-to-person but this may change because of mutation or reassortment with other influenza viruses leading to an influenza pandemic with high mortality. If this occurs travellers are likely to be affected and travel medicine doctors will need to consider avian influenza in returning febrile travellers. The early clinical features may be dismissed easily as ?the flu? resulting in delayed treatment. Treatment options are limited. Oral oseltamivir alone has been the most commonly used drug but mortality remains substantial, up to 80% in Indonesia. Intravenous peramivir has been filed for registration and IV zanamivir is being developed. This review will focus on the epidemiological and clinical features of influenza A/H5N1 avian influenza and will highlight aspects relevant to travel medicine doctors.
Keywords: Avian influenza, Travellers, H5N1, ARDS
a Oxford University Clinical Research Unit, National Institute for Infectious and Tropical Medicine, 78 Giai Street, Hanoi, Viet Nam
b Service de M?decine Internationale et Humanitaire, H?pitaux Universitaires de Gen?ve, rue Micheli-du-Crest 24, 1211, Gen?ve 14, Switzerland
c Departemen Pulmonologi dan Ilmu Kedokteran Respirasi FKUI, Rumah Sakit Persahabatan, Jakarta, Indonesia
d Surgery and Diagnostics Centre, Churchill Hospital, Headington, Oxford, UK
e Geo-Spatial Analyst Infectious Diseases/EMPRES Group, Food and Agriculture Organization, Viale delle Terme di Caracalla, 00100 Rome, Italy
f Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh, Viet Nam
Corresponding author. MORU, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Rd, Bangkok 10400, Thailand. Tel.: +66 22036333.
PII: S1477-8939(09)00162-8
doi:10.1016/j.tmaid.2009.11.006
http://www.travelmedicinejournal.com/article/S1477-8939(09)00162-8/abstract
Avian influenza ? A review for doctors in travel medicine
<form class="form" method="get" name="authors1" action="/search/quick"><input name="search_medline" value="yes" type="hidden"><input name="search_area" value="platform+medline" type="hidden"><input name="restrictname_author" value="author" type="hidden"><input name="restricttype_author" value="author" type="hidden"><input name="restrictterm_author" value="" type="hidden"><input name="restrictdesc_author" value="" type="hidden">W.R.J. Taylorab, E. Burhanc, H. Wertheima, P.Z. Soepandic, P. Horbya, A. Foxa, R. Benamored, L. de Simonee, T.T. Hienf, F. Chappuisb</form>Received 29 October 2009; received in revised form 10 November 2009; accepted 10 November 2009. published online 02 December 2009.
Summary
First identified in humans in Hong Kong, influenza A/H5N1, known commonly as avian influenza, has caused human disease in 15 countries around the world. Although the current number of confirmed patients is tiny compared to seasonal and the recently emerged H1N1 ?swine? influenza, H5N1 remains a candidate for the next highly pathogenic influenza pandemic. Currently, H5N1 has very limited ability to spread from person-to-person but this may change because of mutation or reassortment with other influenza viruses leading to an influenza pandemic with high mortality. If this occurs travellers are likely to be affected and travel medicine doctors will need to consider avian influenza in returning febrile travellers. The early clinical features may be dismissed easily as ?the flu? resulting in delayed treatment. Treatment options are limited. Oral oseltamivir alone has been the most commonly used drug but mortality remains substantial, up to 80% in Indonesia. Intravenous peramivir has been filed for registration and IV zanamivir is being developed. This review will focus on the epidemiological and clinical features of influenza A/H5N1 avian influenza and will highlight aspects relevant to travel medicine doctors.
Keywords: Avian influenza, Travellers, H5N1, ARDS
a Oxford University Clinical Research Unit, National Institute for Infectious and Tropical Medicine, 78 Giai Street, Hanoi, Viet Nam
b Service de M?decine Internationale et Humanitaire, H?pitaux Universitaires de Gen?ve, rue Micheli-du-Crest 24, 1211, Gen?ve 14, Switzerland
c Departemen Pulmonologi dan Ilmu Kedokteran Respirasi FKUI, Rumah Sakit Persahabatan, Jakarta, Indonesia
d Surgery and Diagnostics Centre, Churchill Hospital, Headington, Oxford, UK
e Geo-Spatial Analyst Infectious Diseases/EMPRES Group, Food and Agriculture Organization, Viale delle Terme di Caracalla, 00100 Rome, Italy
f Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh, Viet Nam
PII: S1477-8939(09)00162-8
doi:10.1016/j.tmaid.2009.11.006
http://www.travelmedicinejournal.com/article/S1477-8939(09)00162-8/abstract